Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7400-0.0823 (-10.01%)
At close: 04:00PM EST
0.7500 +0.01 (+1.35%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Long-term KST

Long-term KST

Previous Close0.8223
Open0.8298
Bid0.7410 x 1800
Ask0.7700 x 3100
Day's Range0.7000 - 0.8298
52 Week Range0.7000 - 4.0000
Volume1,452,017
Avg. Volume1,041,595
Market Cap92.671M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.99
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRBP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Corbus Pharmaceuticals Holdings
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement